Natera (NTRA) to Release Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $447.91 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Natera Trading Down 2.4 %

Shares of Natera stock opened at $158.37 on Tuesday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s 50-day simple moving average is $167.73 and its 200-day simple moving average is $146.21. Natera has a 52-week low of $70.71 and a 52-week high of $183.00. The firm has a market cap of $20.91 billion, a price-to-earnings ratio of -89.98 and a beta of 1.66.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. The Goldman Sachs Group lifted their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, TD Cowen increased their price objective on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.94.

Insider Activity

In related news, insider John Fesko sold 663 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the sale, the chief financial officer now directly owns 109,665 shares in the company, valued at $18,091,435.05. This trade represents a 19.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 295,772 shares of company stock valued at $49,741,699 in the last ninety days. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.